# NCT01169337 (NCT01169337)

> Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01169337
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Light Chain Deposition Disease; Smoldering Multiple Myeloma
- Interventions: Clinical Observation; Lenalidomide; Quality-of-Life Assessment
- Enrollment: 226
- Primary outcome: Proportion of Patients With Grade 3 Adverse Events That Effect Vital Organ Function or Any Grade 4 or Higher Non-hematologic Adverse Events (Phase II Primary Endpoint)
- Primary outcome: 2-year Progression-free Survival (PFS) Rate (Phase III Primary Endpoint)

## Commentary we found

- X threads: 11

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct01169337

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01169337", "email": "<work email>"}; the inbox owner confirms by the emailed link.